Welcome to our dedicated page for Vaccinex news (Ticker: VCNX), a resource for investors and traders seeking the latest updates and insights on Vaccinex stock.
Vaccinex, Inc. reports developments as a clinical-stage biotechnology company focused on investigational antibody therapies for neurodegenerative disease and cancer. Its lead program, pepinemab, is an anti-SEMA4D antibody being developed for Alzheimer’s disease and other neurological indications, with additional clinical work in cancer, including head and neck cancer and melanoma immunotherapy settings.
Company news commonly covers pepinemab clinical data presentations, financial results, development financing, and corporate updates tied to listing status and OTC quotation. Vaccinex also reports activity involving its ActivMAb® platform, which uses viral display of complex antigens to support antibody discovery collaborations and project agreements.
Vaccinex (Nasdaq: VCNX) announced a clinical collaboration with Merck to assess the combination of its SEMA4D inhibitor, pepinemab, and Merck's KEYTRUDA® for treating advanced head and neck squamous cell carcinoma (HNSCC). The study will include a dose escalation phase and an expansion phase with up to 65 patients, focusing on enhancing immunotherapy efficacy. Key endpoints will encompass objective response, progression-free survival, and overall survival. Pepinemab has shown promise in preclinical studies for enhancing immune responses in tumors.
Vaccinex, Inc. (Nasdaq: VCNX) announced the appointment of Robert Scala as Chief Commercial Officer, effective immediately. Scala will oversee all commercial functions and strategic operations for the company, starting with pepinemab, a potential treatment for Huntington’s disease. With over 30 years of experience in neurology, oncology, and immunology, Scala previously held leadership roles at biotechnology firms and major pharmaceutical companies. This appointment signifies a pivotal growth phase for Vaccinex, enhancing its commercial capabilities in addressing the unmet needs in Huntington’s disease.
Vaccinex reported its financial results for Q2 2020, raising $19.8 million in funding since June 30. The company anticipates topline data from its SIGNAL trial for Huntington's disease by early October 2020. A Phase 1/2 trial for pepinemab in Alzheimer’s is expected to begin enrolling patients in September. R&D expenses decreased to $4.6 million from $7.3 million in 2019, while general and administrative expenses increased to $1.9 million. Cash and equivalents fell to $0.5 million from $2.8 million at year-end 2019.
Vaccinex, Inc. (VCNX) remains on schedule to complete its pivotal SIGNAL trial for Huntington's disease despite COVID-19 challenges. The trial includes 265 subjects, with data collection almost complete; only two subjects are pending due to pandemic delays. Database lock is expected by September, with topline results anticipated in October. The FDA has approved primary and secondary endpoints for the trial, and initial results show potential cognitive improvements linked to pepinemab treatment. The company aims to advance therapies for Huntington’s and other neurodegenerative diseases.
Vaccinex, a clinical-stage biotechnology firm, will host a Virtual Investor Fireside Chat featuring CEO Maurice Zauderer, Ph.D., on June 16, 2020, at 10:00 AM ET. The event will include a live webcast and an interactive Q&A session for attendees. Vaccinex focuses on developing antibody therapies for Huntington's disease and cancer, with ongoing clinical trials. Investors can access the webcast via the company’s website, where a replay will also be available for one year.
Vaccinex, Inc. (Nasdaq: VCNX) reported its Q1 2020 financial results, showcasing significant developments in its ongoing clinical trials. The company continues its CLASSICAL-Lung study for non-small cell lung cancer (NSCLC) and a SIGNAL trial for Huntington’s disease, with upcoming topline data expected in May 2020. Vaccinex's lead candidate, pepinemab, is also being evaluated for Alzheimer’s disease, though enrollment has been delayed due to COVID-19. Financially, R&D expenses decreased to $5.5 million from $7.4 million year-over-year, with cash and equivalents at $2.5 million.
Vaccinex (Nasdaq: VCNX) announced interim results from the CLASSICAL-Lung Phase 1b/2 study of pepinemab combined with avelumab for non-small cell lung cancer (NSCLC) at the ASCO 2020 Annual Meeting. Key findings show that 59% of patients previously treated with anti-PD-1/PD-L1 therapies exhibited anti-tumor activity after switching to the combination therapy. Additionally, 81% of immunotherapy-naïve patients experienced disease control. The study aims to evaluate the safety and efficacy of this combination treatment, potentially expanding the patient population benefiting from immunotherapy.
Summary not available.